Innealta Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Innealta Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-162	Closed	-$2.51K	–	489
2024 Q2	$2.51K	Buy	+162	New	+$2.52K	﹤0.01%	1023

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Innealta Capital's CPRX Position: Q3 2024 in Review

Innealta Capital sold out of Catalyst Pharmaceutical (CPRX) in Q3 2024, closing a stake of 162 shares — an estimated $2.51K sold.

Innealta Capital first reported a position in CPRX in Q2 2024 and held it in 1 quarter. The position peaked at $2.51K in Q2 2024. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

Innealta Capital reported no remaining Catalyst Pharmaceutical position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 162 Catalyst Pharmaceutical shares in Q3 2024, an estimated $2.51K.
Innealta Capital first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 1 quarter.
Innealta Capital's Catalyst Pharmaceutical position peaked at $2.51K in Q2 2024.
316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.